Physician profile
Francesca Hector
NPI 1013682491
$5,656.95
in general payments reported to CMS, 2019-2025
25 companies · $3,031 in 2025
The $3,031 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.28 · 2024: $2,611 · 2025: $3,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,423 · Travel and Lodging: $1,213 · Education: $6.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,422.58 |
| Travel and Lodging | $1,212.53 |
| Education | $6.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,330.59 | 2024-2025 | Minimed 780g |
| Novo Nordisk INC | $383.88 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $286.07 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $204.40 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $203.22 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $172.11 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $141.53 | 2025 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.63 | 2024-2025 | Jardiance |
| Insulet Corporation | $127.34 | 2024-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $93.23 | 2024-2025 | |
| Dexcom, INC. | $92.78 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $67.16 | 2024-2025 | Evenity, Prolia |
| Kyowa Kirin, INC. | $53.65 | 2024-2025 | Crysvita |
| Tandem Diabetes Care, INC. | $48.66 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Almatica Pharma LLC | $48.25 | 2025 | Teriparatide |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $37.16 | 2025 | |
| Harmony Biosciences LLC | $36.93 | 2024 | |
| Ascensia Diabetes Care US INC. | $31.37 | 2024 | |
| Beta Bionics, INC. | $31.31 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Pfizer INC. | $26.08 | 2024 | |
| Acella Pharmaceuticals, LLC | $24.17 | 2025 | NP Thyroid 60 |
| Sequel Med Tech, LLC | $23.08 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $21.16 | 2025 | Yorvipath |
| Rhythm Pharmaceuticals, INC. | $19.91 | 2024 | Imcivree |
| Abbvie INC. | $15.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Hector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.